January 6, 2022
Matthieu Lamy becomes President of Ad Scientiam, a pioneer in digital biomarkers.
He knows the company well, having joined it five years ago to develop the US market before becoming its CEO in 2020.
He now takes the helm of a fast-evolving company that aims to become the international leader in digital biomarkers for monitoring serious and disabling diseases.
He is supported by Dr. Saad Zinaï as Chief Medical Officer.
We announce the enrollment of the First Patient In in the HARMONY 360 study, conducted in collaboration with Merck KGaA, Darmstadt, Germany, to explore multimodal remote digital monitoring of generalized Myasthenia Gravis with MyoSense 360.
October 8, 2026
At the 12th Congress of the European Academy of Neurology in Geneva, we present the first encouraging 1-year results from our MS-DETECT and MS-FLOWER studies, confirming the reliability of MSCopilot® for long-term monitoring of multiple sclerosis.
June 29, 2026
We announce a decisive step in our international development: the opening of our American subsidiary and the registration of MSCopilot® with the FDA.
April 16, 2026
Talk to our experts and discover how our solutions integrate into your practice or studies.
This site uses analytics cookies
We use Countly to measure audience and improve your experience. This data remains anonymous and is not shared with third parties.